Clinical Trial

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-24
notable Enrollment reduced: 144 -> 105 participants 2026-07-24
notable Trial sites expanded: 2 -> 20 locations 2026-04-18
Trial Details
NCT Number NCT06845202
Lead Sponsor Alnylam Pharmaceuticals
Conditions Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Enrollment 105 participants
Start Date 2025-03-03
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14